Rapid and efficient generation of T-cell receptor-like antibodies using chip-based single-cell analysis.
Rapid and efficient generation of T-cell receptor-like antibodies using chip-based single-cell analysis.
复制标题
使用基于芯片的单细胞分析快速有效地生成 T 细胞受体样抗体。
DOI：
10.1002/eji.202049083
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Kishi H
中科院分区：
文献类型：
--
作者：
Ozawa T;Kobayashi E;Hamana H;Nakamura T;Lyu F;Hayashi A;Muraguchi A;Kishi H
非TCR样抗体不能结合生物素化的靶p/MHC，并且信号不存在或很弱（上，右），而TCR样抗体仅结合生物素化的靶p/MHC，产生明显的信号（下，右）。保留字：ISAAC; TCR; TCR样抗体;肿瘤免疫治疗肿瘤免疫治疗用常规方法产生TCR样单克隆抗体是非常费力和低效的。相反，在阻断的情况下，FI >= 130的9个细胞中的8个（90%）产生TCR样抗体，FI < 130的9个细胞中没有一个产生TCR样抗体（图13）。该研究证明，具有阻断程序的ISAAC可用于产生识别HLA-A24分子上呈递的EBV衍生的BRLF 1肽（BRLF 1 p/HLA-A24）的TCR样抗体。欧洲免疫学杂志的版权是Wiley-Blackwell的财产，未经版权保持器的明确书面许可，其内容不得复制或通过电子邮件发送到多个网站或发布到列表服务器。但是，用户可以打印，下载或电子邮件文章供个人使用。这篇摘要可以删节。不保证副本的准确性。用户应参考原始出版版本的材料的完整摘要。版权适用于所有摘要。
Non-TCR-like antibodies cannot bind biotinylated target p/MHC and signals are absent or weak (top, right), whereas the TCR-like antibody binds only to biotinylated target p/MHC, generating obvious signals (bottom, right). Keywords: ISAAC; TCR; TCR-like antibody; tumor immunotherapy EN ISAAC TCR TCR-like antibody tumor immunotherapy 1850 1853 4 07/05/21 20210701 NES 210701 Generation of TCR-like monoclonal antibodies using conventional methods is markedly laborious and inefficient. In contrast, with the blockade, eight (90%) of nine cells with FI >= 130 produced TCR-like antibodies, and none of the nine cells with FI < 130 produced TCR-like antibodies (Fig. This study demonstrates that ISAAC with blocking procedure is useful to generate TCR-like antibodies recognizing the EBV-derived BRLF1 peptide presented on HLA-A24 molecule (BRLF1p/HLA-A24).[Extracted from the article]Copyright of European Journal of Immunology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. Copyright applies to all Abstracts.